Evidence map›Paper›PMID 38348939›Full record

ArticleCancer medicine2024

Plateletcrit is predictive of clinical outcome and prognosis for early-stage breast cancer: A retrospective cohort study based on propensity score matching.

Xu Zhao, Yilan Yang, Zhe Pan, Weiluo Lv, Xinxin Rao, Xuanyi Wang, Xiaoli Yu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Xu ZhaoDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.ORCID 0000-0003-2933-7937
Yilan YangDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.ORCID 0000-0002-3338-7542
Zhe PanDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Weiluo LvDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Xinxin RaoDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Xuanyi WangDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Xiaoli YuDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.ORCID 0000-0003-1247-7896
Shanghai Medical College of Fudan University · CN

Funding

National Natural Science Foundation of China 81972846
6 · The paper itself

Abstract

purposeBreast cancer (BC) is diagnosed as the most common cancer in women in 2022 according to the American Cancer Society. It is essential to detect early and treat early. Several studies have shown that some blood parameters have important predictive value for BC. In this study, we aim to explore whether some immune-associated blood parameters are relevant to disease-free survival (DFS) in early-stage BC.

methodsA single-center, regression cohort study of 1490 patients with early-stage BC in Shanghai Cancer Center was conducted from January 2008 to December 2016. The patients were matched according to the ratio of 1:1 based on Propensity Score Matching (PSM). All patients who experienced disease progression were matched successfully. Thus, 58 pairs of subjects were obtained. Matched blood parameters were evaluated by paired samples t-test or Wilcoxon signed-rank test. Factors with statistical difference were further evaluated by stratified COX regression model.

resultsUnivariate analysis showed differences in platelet-related parameters (PLT, PCT, and PLR) and NLR between the two matched groups. However, stratified COX regression analysis, which ruled out the confounding effects of multiple factors, found that only PCT had prognostic value in early BC patients at baseline and study endpoint. Meanwhile, platelet-related parameters (PLT, MPV) and NLR were different in the progressive group by self before and after comparison. However, the multiple-factor analysis showed that only the NLR had prognostic value. ROC curve analysis indicated that the best sensitivity (65.45%) and specificity (78.18%) were obtained when the baseline PCT was 0.225. The optimal sensitivity (70.91%) and specificity (65.45%) were obtained when the PCT of disease progression was 0.215. The Kaplan-Meier curve was used to calculate the DFS rate based on the critical values of the two groups.

conclusionsSome blood parameters have value to predict DFS in early-stage BC patients, especially platelet-associated parameters.

Indexed as

Blood PlateletsBreast NeoplasmsChinaCohort StudiesDisease ProgressionFemaleHumansLymphocytesNeutrophilsPlatelet CountPrognosisPropensity ScoreRetrospective Studiesblood parametersdisease-free survivalearly-stage breast cancerplateletcrit

Identifiers

PMID38348939
PMCPMC10832319
OpenAlexW4391436253

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.